<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>ACR 2025 Vasculitis Resources | Alison Bays, MD</title>
    <style>
        :root {
            --deep-blue: #19375f;
            --blue-med: #2d5587;
            --pale-pink: #ffe4e9;
            --pink-accent: #ffc0cb;
            --cream: #fffcfa;
            --white: #ffffff;
            --black: #232323;
        }
        
        * { margin: 0; padding: 0; box-sizing: border-box; }
        
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            background: var(--cream);
            color: var(--black);
            line-height: 1.6;
        }
        
        header {
            background: linear-gradient(135deg, var(--deep-blue) 0%, var(--blue-med) 100%);
            color: var(--white);
            padding: 2.5rem 1rem;
            text-align: center;
            border-bottom: 6px solid var(--pale-pink);
        }
        
        header h1 { font-size: 2.5rem; margin-bottom: 0.5rem; }
        header p { font-size: 1.2rem; color: var(--pale-pink); }
        
        .container { max-width: 1100px; margin: 0 auto; padding: 2rem 1rem; }
        
        .section {
            background: var(--white);
            border-radius: 12px;
            padding: 1.8rem;
            margin-bottom: 1.5rem;
            box-shadow: 0 4px 15px rgba(25, 55, 95, 0.1);
            border-left: 5px solid var(--deep-blue);
        }
        
        .section.highlight {
            border-left-color: var(--pink-accent);
            background: linear-gradient(to right, #fff8f9, var(--white));
        }
        
        .section h2 {
            color: var(--deep-blue);
            font-size: 1.5rem;
            margin-bottom: 1rem;
        }
        
        .section h3 {
            color: var(--blue-med);
            font-size: 1.1rem;
            margin: 1rem 0 0.5rem 0;
        }
        
        .abstract-list { list-style: none; padding: 0; }
        
        .abstract-list li {
            padding: 0.8rem 1rem;
            margin: 0.5rem 0;
            background: var(--cream);
            border-radius: 8px;
            border-left: 3px solid var(--pale-pink);
        }
        
        .abstract-list li:hover {
            background: #f0f5fa;
            border-left-color: var(--deep-blue);
        }
        
        .abstract-num {
            font-weight: bold;
            color: var(--deep-blue);
            margin-right: 0.5rem;
        }
        
        a { color: var(--blue-med); text-decoration: none; }
        a:hover { color: var(--deep-blue); text-decoration: underline; }
        
        .key-trial {
            background: linear-gradient(to right, var(--pale-pink), #fff0f3);
            padding: 1rem 1.2rem;
            border-radius: 8px;
            margin: 0.8rem 0;
        }
        
        .key-trial h4 { color: var(--deep-blue); margin-bottom: 0.3rem; }
        
        .badge {
            display: inline-block;
            padding: 0.2rem 0.6rem;
            border-radius: 12px;
            font-size: 0.75rem;
            font-weight: bold;
            margin-left: 0.5rem;
        }
        
        .badge-gca { background: var(--deep-blue); color: var(--white); }
        .badge-egpa { background: var(--pink-accent); color: var(--deep-blue); }
        .badge-aav { background: var(--blue-med); color: var(--white); }
        .badge-igg4 { background: #9370db; color: var(--white); }
        
        .links-section {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));
            gap: 1rem;
            margin-top: 1rem;
        }
        
        .link-card {
            background: var(--cream);
            padding: 1.2rem;
            border-radius: 8px;
            text-align: center;
            transition: transform 0.2s, box-shadow 0.2s;
        }
        
        .link-card:hover {
            transform: translateY(-3px);
            box-shadow: 0 6px 20px rgba(25, 55, 95, 0.15);
        }
        
        .link-card h4 { color: var(--deep-blue); margin-bottom: 0.5rem; }
        
        footer {
            background: var(--deep-blue);
            color: var(--white);
            text-align: center;
            padding: 2rem 1rem;
            margin-top: 2rem;
        }
        
        footer a { color: var(--pale-pink); }
        
        .footer-links {
            margin-top: 1rem;
            display: flex;
            justify-content: center;
            gap: 2rem;
            flex-wrap: wrap;
        }
        
        .footer-links a {
            display: inline-flex;
            align-items: center;
            gap: 0.5rem;
            padding: 0.5rem 1rem;
            background: rgba(255,255,255,0.1);
            border-radius: 6px;
            transition: background 0.2s;
        }
        
        .footer-links a:hover {
            background: rgba(255,255,255,0.2);
            text-decoration: none;
        }
        
        @media (max-width: 600px) {
            header h1 { font-size: 1.8rem; }
            .section { padding: 1.2rem; }
        }
    </style>
</head>
<body>
    <header>
        <p style="font-size: 1.1rem; margin-bottom: 0.3rem;"><strong>Alison Bays, MD</strong></p>
        <p style="font-size: 0.95rem; margin-bottom: 0.8rem;">
            <a href="https://rheumify.org" target="_blank" style="color: var(--pale-pink);">üåê Rheumify.org</a>
            &nbsp;‚Ä¢&nbsp;
            <a href="https://rheumify.substack.com/" target="_blank" style="color: var(--pale-pink);">üì∞ Substack</a>
        </p>
        <h1>ü©∫ ACR Convergence 2025</h1>
        <p>Vasculitis Highlights & Resources</p>
        <p style="margin-top: 0.5rem; font-size: 1rem; color: #fff;">Chicago, IL ‚Ä¢ November 14-19, 2025</p>
    </header>
    
    <div class="container">
        <!-- KEY TRIALS -->
        <div class="section highlight">
            <h2>üîë Key Trials & Publications</h2>
            
            <div class="key-trial">
                <h4>SELECT-GCA (NEJM 2025) <span class="badge badge-gca">GCA</span></h4>
                <p>Upadacitinib 15mg superior to placebo (46.4% vs 29.0%, p=0.002). 7.5mg NOT superior. No MACE. N=428.</p>
                <p><a href="https://acrabstracts.org/abstract/efficacy-and-safety-of-upadacitinib-in-patients-with-giant-cell-arteritis-select-gca-a-double-blind-randomized-controlled-phase-3-trial/" target="_blank">‚Üí ACR Abstract</a> &nbsp;|&nbsp; <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2413449" target="_blank">‚Üí NEJM Publication</a></p>
            </div>
            
            <div class="key-trial">
                <h4>METOGiA Trial (ACR 2025) <span class="badge badge-gca">GCA</span></h4>
                <p>MTX vs TCZ: MTX 37% vs TCZ 46% sustained remission at week 78. MTX NOT non-inferior (p=0.054). N=218. Safety concern: 5 Pneumocystis infections with MTX (1 fatal).</p>
                <p><a href="https://acrabstracts.org/abstract/methotrexate-versus-tocilizumab-for-treatment-of-giant-cell-arteritis-metogia-trial-a-multicenter-randomized-controlled-trial/" target="_blank">‚Üí ACR Abstract</a></p>
            </div>
            
            <div class="key-trial">
                <h4>MANDARA (NEJM 2024) <span class="badge badge-egpa">EGPA</span></h4>
                <p>Benralizumab non-inferior to mepolizumab (58% vs 56%). Fewer serious AEs (6% vs 13%). N=140.</p>
                <p><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2311155" target="_blank">‚Üí NEJM Publication</a></p>
            </div>
            
            <div class="key-trial">
                <h4>MITIGATE Trial (ACR 2025) <span class="badge badge-igg4">IgG4-RD</span></h4>
                <p>Inebilizumab (CD19 B-cell depleting mAb): 87% reduction in flare risk vs placebo. Phase 3 data. N=135.</p>
                <p><a href="https://acrabstracts.org/abstract/a-phase-3-randomized-double-blind-multicenter-placebo-controlled-study-of-inebilizumab-in-igg4-related-disease-mitigate-primary-efficacy-and-safety-findings/" target="_blank">‚Üí ACR Abstract</a></p>
            </div>
        </div>
        
        <!-- GCA ABSTRACTS -->
        <div class="section">
            <h2>üî¨ Giant Cell Arteritis Abstracts</h2>
            
            <h3>SELECT-GCA & Upadacitinib</h3>
            <ul class="abstract-list">
                <li>
                    <a href="https://acrabstracts.org/abstract/efficacy-and-safety-of-upadacitinib-in-patients-with-giant-cell-arteritis-select-gca-a-double-blind-randomized-controlled-phase-3-trial/" target="_blank">SELECT-GCA: Phase 3 Trial Results (N=428)</a>
                </li>
                <li>
                    <a href="https://acrabstracts.org/abstract/efficacy-and-safety-of-upadacitinib-in-giant-cell-arteritis-2-year-results-from-the-re-randomized-double-blind-select-gca-phase-3-trial/" target="_blank">SELECT-GCA 2-Year Results</a>
                </li>
                <li>
                    <span class="abstract-num">#0895</span>
                    <a href="https://acrabstracts.org/abstract/efficacy-of-upadacitinib-in-patients-with-giant-cell-arteritis-subgroup-analysis-of-the-select-gca-phase-3-trial/" target="_blank">Glucocorticoid tapering subgroup analysis</a>
                </li>
                <li>
                    <span class="abstract-num">#0892</span>
                    Y chromosome loss linked to GCA relapse (novel mechanistic insight)
                </li>
                <li>
                    <span class="abstract-num">#0737</span>
                    Real-world JAK inhibitor effectiveness in GCA
                </li>
            </ul>
            
            <h3>METOGiA & Tocilizumab Studies</h3>
            <ul class="abstract-list">
                <li>
                    <a href="https://acrabstracts.org/abstract/methotrexate-versus-tocilizumab-for-treatment-of-giant-cell-arteritis-metogia-trial-a-multicenter-randomized-controlled-trial/" target="_blank">METOGiA: MTX vs TCZ for GCA (N=218) - Multicenter RCT</a>
                </li>
            </ul>
            
        </div>
        
        <!-- EGPA ABSTRACTS -->
        <div class="section">
            <h2>üî¨ EGPA Abstracts</h2>

            <h3>MANDARA Trial & Anti-IL5 Therapy</h3>
            <ul class="abstract-list">
                <li>
                    <a href="https://acrabstracts.org/abstract/efficacy-of-eosinophil-targeting-therapies-on-specific-disease-manifestations-of-eosinophilic-granulomatosis-with-polyangiitis-in-the-phase-3-mandara-trial/" target="_blank">MANDARA 2-Year: Efficacy on specific disease manifestations (ACR 2025)</a>
                </li>
                <li>
                    <a href="https://acrabstracts.org/abstract/classification-of-relapses-of-eosinophilic-granulomatosis-with-polyangiitis-after-two-years-of-treatment-with-anti-interleukin-5-receptor-therapy/" target="_blank">MANDARA 2-Year: Classification of relapses after anti-IL5/R therapy (ACR 2025)</a>
                </li>
                <li>
                    <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2311155" target="_blank">MANDARA Primary Results - NEJM 2024</a>
                </li>
            </ul>
        </div>
        
        <!-- AAV ABSTRACTS -->
        <div class="section">
            <h2>üî¨ ANCA-Associated Vasculitis Abstracts</h2>
            
            <h3>Avacopan & Safety</h3>
            <ul class="abstract-list">
                <li>
                    <a href="https://acrabstracts.org/abstract/risk-of-drug-induced-liver-injury-with-use-of-avacopan-in-anca-vasculitis-results-from-real-world-data/" target="_blank">Avacopan liver injury risk: Real-world data (N=29,163) - elevated ROR=17.59</a>
                </li>
                <li>
                    <a href="https://acrabstracts.org/abstract/safety-of-avacopan-in-anca-associated-vasculitis-combined-data-from-three-clinical-trials/" target="_blank">Avacopan Safety: Combined data from three clinical trials</a>
                </li>
                <li>
                    <a href="https://acrabstracts.org/abstract/real-world-experience-with-avacopan-in-anca-vasculitis-a-multi-center-retrospective-cohort-analysis/" target="_blank">Real-world Avacopan experience: Multicenter retrospective analysis</a>
                </li>
                <li>
                    <a href="https://acrabstracts.org/abstract/avacopan-is-not-associated-with-an-increased-risk-of-infection-compared-to-glucocorticoids-in-patients-with-anca-associated-vasculitis/" target="_blank">Avacopan infection risk vs glucocorticoids: No increased risk</a>
                </li>
            </ul>

            <h3>Outcomes & Prognostic Tools</h3>
            <ul class="abstract-list">
                <li>
                    <span class="abstract-num">#2521</span>
                    <a href="https://acrabstracts.org/abstract/danger-score-as-predictor-of-mortality-in-anca-associated-vasculitis-with-or-without-glomerulonephritis-data-from-the-almenara-vasculitis-cohort/" target="_blank">DANGER Score: Mortality predictor in AAV ¬± glomerulonephritis</a>
                </li>
            </ul>

            <h3>Trial Diversity & Equity</h3>
            <ul class="abstract-list">
                <li>
                    <span class="abstract-num">#1842</span>
                    <a href="https://acrabstracts.org/abstract/reporting-of-race-ethnicity-sex-gender-socioeconomic-status-and-representativeness-of-race-and-ethnicity-in-anca-associated-vasculitis-randomized-trials/" target="_blank">Diversity in AAV & GCA Clinical Trials: Race/ethnicity in only 20% of 45 RCTs</a>
                </li>
            </ul>
        </div>
        
        <!-- IgG4-RD ABSTRACTS -->
        <div class="section">
            <h2>üî¨ IgG4-Related Disease Abstracts</h2>
            
            <h3>MITIGATE Trial & Inebilizumab</h3>
            <ul class="abstract-list">
                <li>
                    <a href="https://acrabstracts.org/abstract/a-phase-3-randomized-double-blind-multicenter-placebo-controlled-study-of-inebilizumab-in-igg4-related-disease-mitigate-primary-efficacy-and-safety-findings/" target="_blank">MITIGATE Phase 3: Inebilizumab primary efficacy & safety (87% flare reduction)</a>
                </li>
                <li>
                    <a href="https://acrabstracts.org/abstract/clinical-and-biomarker-characteristics-of-inebilizumab-treated-participants-who-experienced-an-igg4-rd-flare-during-the-phase-3-mitigate-trial/" target="_blank">MITIGATE Biomarker Analysis: B cells, IgG4 levels, and flare characteristics</a>
                </li>
                <li>
                    <a href="https://acrabstracts.org/abstract/inebilizumab-efficacy-and-safety-in-patients-with-common-urgent-and-fibrotic-organ-manifestations-of-igg4-rd-subgroup-analyses-from-the-mitigate-trial/" target="_blank">MITIGATE Subgroup Analysis: Common, urgent & fibrotic organ manifestations</a>
                </li>
            </ul>
            
            
            <h3>Treatment & Management</h3>
            <ul class="abstract-list">
                <li>
                    <span class="abstract-num">LB02</span>
                    <a href="https://acrabstracts.org/abstract/tofacitinib-plus-glucocorticoids-can-effectively-reduce-relapse-rate-in-igg4-related-disease-a-randomizedopen-label-controlled-trial/" target="_blank">‚≠ê LATE-BREAKING: Tofacitinib + GC significantly reduces relapse rate (RCT)</a>
                </li>
                <li>
                    <a href="https://acrabstracts.org/abstract/safety-of-rilzabrutinib-a-btk-inhibitor-in-adult-patients-with-igg4-related-disease-igg4-rd-in-a-52-week-phase-2-open-label-study/" target="_blank">Rilzabrutinib (BTK inhibitor): 70% off GC & flare-free at 52 weeks</a>
                </li>
                <li>
                    <a href="https://acrabstracts.org/abstract/factors-associated-with-long-term-remission-after-drug-discontinuation-in-igg4-related-disease-a-3-year-rule/" target="_blank">Long-term remission after drug discontinuation: The 3-year rule</a>
                </li>
                <li>
                    <a href="https://acrabstracts.org/abstract/diagnostic-journey-clinical-burden-and-quality-of-life-of-patients-with-igg4-related-disease-results-of-a-cross-sectional-survey-of-patients-and-physicians-in-the-united-states/" target="_blank">Diagnostic journey & QoL: US patient/physician survey</a>
                </li>
            </ul>
        </div>
        
        <!-- OTHER VASCULITIS -->
        <div class="section">
            <h2>üî¨ Other Vasculitis Abstracts</h2>

            <h3>IgA Vasculitis & Small Vessel</h3>
            <ul class="abstract-list">
                <li>
                    <a href="https://acrabstracts.org/abstract/cutaneous-iga-vasculitis-emulation-of-a-target-trial-from-a-european-multicentric-retrospective-study/" target="_blank">Cutaneous IgA Vasculitis: Target trial comparing colchicine vs dapsone vs GC</a>
                </li>
            </ul>

            <h3>Takayasu Arteritis</h3>
            <ul class="abstract-list">
                <li>
                    <a href="https://acrabstracts.org/abstract/development-of-the-takayasus-arteritis-integrated-disease-activity-index/" target="_blank">TAIDAI: New Takayasu's Arteritis Integrated Disease Activity Index</a>
                </li>
            </ul>

            <h3>Large Vessel Vasculitis Guidelines</h3>
            <ul class="abstract-list">
                <li>
                    <a href="https://acrabstracts.org/abstract/a-systematic-literature-review-to-inform-the-2025-eular-recommendations-for-management-of-polymyalgia-rheumatica-and-large-vessel-vasculitis-management-of-disease-including-relapse-and-complications/" target="_blank">2025 EULAR PMR & LVV Recommendations: Systematic review</a>
                </li>
            </ul>
        </div>

        <!-- GUIDELINES -->
        <div class="section">
            <h2>üìã Guidelines & Resources</h2>
            
            <div class="links-section">
                <div class="link-card">
                    <h4>BSR 2025 AAV Guidelines</h4>
                    <p>Updated management recommendations</p>
                    <a href="https://academic.oup.com/rheumatology/article/64/8/4470/8160140" target="_blank">View Guidelines ‚Üí</a>
                </div>
                
                <div class="link-card">
                    <h4>ACR/VF GCA & TAK Guidelines</h4>
                    <p>2021 Management Guidelines</p>
                    <a href="https://rheumatology.org/vasculitis-guideline" target="_blank">View Guidelines ‚Üí</a>
                </div>
                
                <div class="link-card">
                    <h4>Vasculitis Foundation</h4>
                    <p>Patient & Provider Resources</p>
                    <a href="https://vasculitisfoundation.org/" target="_blank">Visit Site ‚Üí</a>
                </div>
                
                <div class="link-card">
                    <h4>ACR Abstract Database</h4>
                    <p>Search all ACR 2025 abstracts</p>
                    <a href="https://acrabstracts.org/" target="_blank">Search Abstracts ‚Üí</a>
                </div>
            </div>
        </div>
    </div>
    
    <footer>
        <p>Compiled by <strong>Alison Bays, MD</strong></p>
        <p style="margin-top: 0.5rem;">ACR Convergence 2025 ‚Ä¢ Chicago, IL</p>
        
        <div class="footer-links">
            <a href="https://rheumify.org" target="_blank">
                üåê Rheumify.org
            </a>
            <a href="https://rheumify.substack.com/" target="_blank">
                üì∞ Rheumify Substack
            </a>
        </div>
        
        <p style="margin-top: 1.5rem; font-size: 0.9rem; color: var(--pale-pink);">
            For educational purposes only. Always verify with primary sources.
        </p>
    </footer>
</body>
</html>
